Epoch Investment Partners’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$76.6M Sell
549,365
-47,960
-8% -$6.72M 0.46% 84
2025
Q4
$73.3M Sell
597,325
-39,610
-6% -$4.81M 0.42% 94
2025
Q3
$70.7M Sell
636,935
-221,339
-26% -$25.2M 0.39% 98
2025
Q2
$95.2M Buy
858,274
+743,235
+646% +$79.1M 0.49% 74
2025
Q1
$12.9M Buy
+115,039
New +$11.9M 0.07% 199
2024
Q4
Sell
-13,632
Closed -$1.14M 325
2024
Q3
$1.14M Sell
13,632
-1,992
-13% -$152K 0.01% 294
2024
Q2
$1.07M Sell
15,624
-872,354
-98% -$58.2M ﹤0.01% 305
2024
Q1
$65M Buy
887,978
+139,907
+19% +$10.8M 0.29% 122
2023
Q4
$60.6M Buy
748,071
+247,652
+49% +$19.3M 0.28% 139
2023
Q3
$37.5M Sell
500,419
-52,093
-9% -$4.01M 0.24% 142
2023
Q2
$42.6M Sell
552,512
-20,149
-4% -$1.61M 0.25% 144
2023
Q1
$47.5M Sell
572,661
-293,278
-34% -$24.3M 0.28% 123
2022
Q4
$74.3M Sell
865,939
-32,217
-4% -$2.55M 0.44% 75
2022
Q3
$55.4M Sell
898,156
-23,476
-3% -$1.48M 0.36% 97
2022
Q2
$57M Buy
921,632
+96,437
+12% +$5.97M 0.33% 105
2022
Q1
$49.1M Buy
825,195
+116,195
+16% +$7.43M 0.24% 135
2021
Q4
$51.5M Buy
709,000
+123,883
+21% +$8.53M 0.26% 137
2021
Q3
$40.9M Sell
585,117
-15,013
-3% -$1.05M 0.23% 135
2021
Q2
$41.3M Buy
+600,130
New +$40.1M 0.22% 137
2018
Q1
Sell
-27,545
Closed -$1.97M 318
2017
Q4
$1.97M Sell
27,545
-108
-0.4% -$8.2K 0.01% 273
2017
Q3
$2.24M Hold
27,653
0.01% 271
2017
Q2
$1.96M Buy
27,653
+20,473
+285% +$1.36M 0.01% 273
2017
Q1
$488K Buy
+7,180
New +$505K ﹤0.01% 306
2016
Q3
Sell
-4,340,442
Closed -$362M 293
2016
Q2
$362M Sell
4,340,442
-479,860
-10% -$42.6M 1.36% 21
2016
Q1
$443M Buy
4,820,302
+580,832
+14% +$52.4M 1.67% 10
2015
Q4
$429M Sell
4,239,470
-118,038
-3% -$12.3M 1.7% 12
2015
Q3
$428M Buy
4,357,508
+1,534,399
+54% +$170M 1.66% 10
2015
Q2
$331M Buy
2,823,109
+2,815,544
+37,218% +$308M 1.22% 19
2015
Q1
$742K Buy
+7,565
New +$768K ﹤0.01% 243

Other funds holding GILD

Epoch Investment Partners's GILD Position: Q1 2026 in Review

Epoch Investment Partners reduced its Gilead Sciences (GILD) stake by 8% in Q1 2026, selling an estimated $6.72M and leaving 549,365 shares worth $76.6M. The position accounts for 0.46% of the portfolio, ranked #84.

Epoch Investment Partners first reported a position in GILD in Q1 2015 and has held it in 29 quarters since. The position peaked at $443M in Q1 2016. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • Epoch Investment Partners held 549,365 shares of Gilead Sciences worth $76.6M as of Q1 2026.
  • Epoch Investment Partners sold 47,960 Gilead Sciences shares in Q1 2026, an estimated $6.72M.
  • Gilead Sciences made up 0.46% of Epoch Investment Partners's portfolio in Q1 2026, its #84 holding.
  • Epoch Investment Partners first reported a position in Gilead Sciences in Q1 2015 and has held it in 29 quarters since.
  • Epoch Investment Partners's Gilead Sciences position peaked at $443M in Q1 2016.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Epoch Investment Partners's 13F filing for Q1 2026, filed 14 May 2026.